ACP-105
Appearance
![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H19ClN2O |
Molar mass | 290.79 g·mol−1 |
3D model (JSmol) | |
| |
|
ACP-105 is a drug which acts as a selective androgen receptor modulator (SARM). It has been investigated for potential use in the treatment of age-related cognitive decline.[1][2][3][4] The drug has been found to reduce anxiety-like behavior in a mouse model of Alzheimer's disease when administered alone, as well as enhance spatial memory when coadministered with the selective estrogen receptor
References
[edit]- ^ Schlienger N, Lund BW, Pawlas J, Badalassi F, Bertozzi F, Lewinsky R, et al. (November 2009). "Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators". Journal of Medicinal Chemistry. 52 (22): 7186–7191. doi:10.1021/jm901149c. PMID 19856921.
- ^ Dayger C, Villasana L, Pfankuch T, Davis M, Raber J (March 2011). "Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice". Brain Research. 1381: 134–140. doi:10.1016/j.brainres.2010.12.088. PMC 3048897. PMID 21219889.
- ^ a b George S, Petit GH, Gouras GK, Brundin P, Olsson R (December 2013). "Nonsteroidal selective androgen receptor modulators and selective estrogen receptor
β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease". ACS Chemical Neuroscience. 4 (12): 1537–1548. doi:10.1021/cn400133s. PMC 3867967. PMID 24020966. - ^ Cutler C, Viljanto M, Taylor P, Hincks P, Biddle S, Van Eenoo P (October 2021). "Identification of equine in vitro metabolites of seven non-steroidal selective androgen receptor modulators for doping control purposes". Drug Testing and Analysis. 14 (2): 349–370. doi:10.1002/dta.3189. hdl:1854/LU-8740373. PMID 34714606. S2CID 240152623.
- ^ Zhang X, Sui Z (February 2013). "Deciphering the selective androgen receptor modulators paradigm". Expert Opinion on Drug Discovery. 8 (2): 191–218. doi:10.1517/17460441.2013.741582. PMID 23231475. S2CID 2584722.